ReviewGeriatrics & gerontology international2026
Peripheral Insulin Resistance and Alzheimer's Disease: Possible Mediators Including Extracellular Vesicles.
Review in Geriatrics & gerontology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epidemiological studies consistently indicate that type 2 diabetes mellitus increases the risk of Alzheimer's disease (AD). Accumulating evidence suggests that insulin resistance, rather than hyperglycemia per se, is the principal metabolic factor associated with AD development. Population-based longitudinal studies show that insulin resistance is strongly linked to earlier amyloid β (Aβ) accumulation, whereas its association with tau pathology remains inconsistent. Importantly, insulin resistance-related cognitive decline and earlier disease onset cannot be fully explained by the extent of Aβ deposition alone, implying the involvement of additional pathogenic pathways. Animal studies further support a role for insulin resistance independent of sustained hyperglycemia. Genetic models of systemic insulin resistance demonstrate impairments in cognition, cerebral blood flow regulation, and emotional behavior, distinct from phenotypes observed in models with brain-specific disruption of insulin signaling. Together with clinical observations showing preserved central insulin responsiveness in individuals with type 2 diabetes, these findings highlight peripheral insulin resistance as a key contributor to brain vulnerability in AD. How peripheral insulin resistance influences the brain remains incompletely understood. Emerging evidence suggests that extracellular vesicles may act as a possible mediator of peripheral-central communication by conveying bioactive molecules across tissues. In this review, we summarize epidemiological and experimental evidence linking peripheral insulin resistance to AD and discuss the potential, yet still speculative, role of extracellular vesicles in this process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.